INTRODUCTION N
Atopicc dermatitis, an inflammatory skin disease with a chronically relapsing course,, is characterized by episodes of intense pruritus, multiple lesions with erythema,, excoriation, erosions accompanied by a serous exudate, accentuated skinn markings (lichenification), fibrotic papules, severely dry skin, and a susceptibilityy to cutaneous infections. Atopic dermatitis often coexists with otherr atopic diseases, especially allergic respiratory diseases. There are no biochemicall markers for atopic dermatitis, but patients typically have elevated serumm IgE levels, eosinophil counts, and lactate dehydrogenase concentrations.. 1-4 Topical corticosteroids are the standard treatment for acute lesionss of atopic dermatitis. However, they carry a risk of local side effects such ass skin atrophy and striae and systemic side effects. Thus, use of high-potency topicall corticosteroids is indicated only for short periods and for a limited area off treatment. Weak topical corticosteroids are preferred for regions of skin that aree particularly thin and more susceptible to skin atrophy, such as the face.2 Tacrolimuss ointment is the first potential new topical therapy for atopic dermatitiss since the introduction of corticosteroids some 40 years ago. Tacrolimuss is a novel macrolide molecule discovered for its ability to inhibit T-celll activation. 5 SDZ ASM has a structure and activity similar to tacrolimus andd might also be efficacious in atopic dermatitis when applied topically.6 The locall action of tacrolimus on the skin of patients with atopic dermatitis seems to involvee T cells, Langerhans cells, mast cells, and basophils.7 Short-term studies8-100 in adults and children have shown that tacrolimus ointment is effectivee and safe in the treatment of atopic dermatitis. Systemic absorption is minimal.. 11 Unlike topical corticosteroids, tacrolimus ointment does not cause skinn atrophy; 7 days of application under occlusion in adults did not compromisee collagen synthesis or cause skin thinning. 12 Because atopic dermatitiss is a chronic disease, there is a need for long-term assessment of patientss treated with tacrolimus ointment. This study was undertaken to assess thee safety and efficacy of tacrolimus ointment monotherapy for either 6 or 12 monthss in patients with moderate to severe atopic dermatitis.
PATIENTSS AND METHODS

Studyy design
Thee primary focus of this long-term, open-label, noncomparative, multicenter phasee 3 study was to assess the long-term safety of 0.1% tacrolimus ointment in adultss with atopic dermatitis. The study was performed at 30 centers in 11 Europeann countries; the ethics committee of each center reviewed the protocol andd granted approval of the study before its implementation. Patients were assignedd to either 6 or 12 months of study participation at entry. It was planned too enroll approximately 300 patients, with the first 120 to be assigned 12 monthss of participation. The sample size and duration of exposure were based onn guidelines from the International Conference on Harmonisation that describe thee extent of population exposure required to assess clinical safety with long-termm use of a drug. 13 The study consisted of a screening visit within 30 dayss before the baseline visit; a baseline visit (day 1); visits 1, 2, and 4 weeks afterr treatment initiation; and monthly visits thereafter.
Patientt selection
Menn and women aged 18 years and older with a diagnosis of atopic dermatitis basedd on the criteria of Hanifin and Rajkal4 were eligible for study participation.. Patients were also required to have an atopic dermatitis severity gradingg of moderate to severe according to the criteria of Rajka and Langelandl55 and disease involvement of 5% to 60% of the total body surface area.. The main exclusion criterion was a serious skin disorder other than atopic dermatitis.. All patients gave informed consent.
Treatment t
Att baseline, investigators assessed areas to be treated, dispensed the first ointmentt supply box, and explained the dosing procedure to the patient. Treatmentt consisted of a thin coat of 0.1% tacrolimus ointment applied twice dailyy to areas of actively diseased skin. The treatment area could extend up to 60%oo of the total body surface area; this was extended to 100%o of the total body surfacee area by protocol amendment after all patients had been enrolled. Patientss were instructed to continue application for 1 week after cessation of itchh and to change the treatment areas or select new areas based on the presence off itch. The treated area was assessed by the investigator at each study visit. Prohibitedd therapies were other investigational drugs, UV-A and UV-B light treatments,, nonsteroidal immunosuppressive agents, and topical corticosteroids. Restrictedd therapies included systemic corticosteroids (2 treatment periods of 2 weekss each separated by 3 months and no treatment within the 4 weeks precedingg the Recall Antigen Test) and nonsteroidal anti-inflammatory drugs (2 weekss of treatment within any 3-month period). Allowed therapies were bath oil,, nonmedicated emollients, inhaled corticosteroids (patients with an immediatee history of taking >1 mg/d were excluded), antihistamines, and anti-infectivee agents. ASSESSMENTS Adverse events were monitored on an ongoingg basis. An adverse event was defined as any undesirable experience that occurredd to a patient during the clinical trial regardless of whether it was consideredd to be related to use of the study drug. "Causally related" adverse eventss were those assessed by the investigator as having a highly probable, probable,, possible, not assessable relation to the study drug or adverse events forr which such an assessment was not made. Except as noted, adverse event dataa are presented irrespective of the causality assessment.
Laboratory assessmentss (hematology, clinical chemistry, and renal and hepatic function) weree performed at the screening visit; day 1; weeks 1, 2, and 4; and once a monthh thereafter. The Recall Antigen Test was used at selected centers (based onn experience) to assess delayed-type hypersensitivity reactions as an indirect measuree of cellular immune response (Multitest CMI; Institut Mérieux, Lyon, France).. At baseline and after 6 and 12 months, skin testing was carried out usingg an 8-pronged applicator containing 7 preloaded antigens and 1 vehicle control.. Results were given as the sum of the diameters from positive reactions (Mérieuxx score) and the mean number of positive reactions. 16 A test reaction of att least 2 mm in diameter (the mean of the maximum diameter and the diameter orthogonall to it) was regarded as positive. For determination of tacrolimus concentrations,, whole blood samples were collected at day 1, week 1, week 2, monthh 1, month 3, and the last visit. The samples were assayed for tacrolimus concentrationn using a validated high-performance liquid chromatography methodd with repeated mass spectrometry. The limit of quantification was 0.025 ng/mL;; intra-assay precision was 14.7% of the quantification limit. 17 On day 1 off treatment; weeks 1, 2, and 4; and once a month thereafter, investigators rated erythema,, edema/induration/papulation, excoriations, and lichenification on a scalee from 0 to 3 and estimated the percentage of total body surface area affectedd by atopic dermatitis (0%-100%) for 4 body regions (head and neck, trunk,, upper limbs, and lower limbs). Patients assessed the intensity of itch experiencedd during the previous 24 hours using a 10-cm visual analog scale, withh 0 cm indicating "no itch" and 10 cm indicating "worst itch imaginable." Thesee assessments were used to calculate the modified Eczema Area and Severityy Index (mEASI). The mEASI is a variant of the EASE 18 The mEASI is identicall to the EASI except that in the latter an assessment of itch is not included.. Itch was included in the mEASI because it is considered a primary symptomm of atopic dermatitis. 14 The EASI and the mEASI have the advantage off including severity scores for individual symptoms of atopic dermatitis weightedd according to the extent of affected body surface area. For each body regionn (head and neck, upper limbs, trunk, and lower limbs), the following steps weree carried out: (1) an affected area score of 0 to 6 was assigned for the percentagee of affected body surface area (0%-100%); (2) the individual ratings forr erythema, edema/induration/papulation, excoriations, and lichenification weree summed (0-3 for each of the 4 symptoms); (3) the sum of the individual symptomss (maximum = 12) was multiplied by the affected area score (maximumm = 6) for a maximum of 72; (4) the head and neck subtotal was multipliedd by 0.1, the upper limb subtotal by 0.2, the trunk subtotal by 0.3, and thee lower limb subtotal by 0.4, and all components were summed (maximum EASII = 72); and (5) the patient's assessment of itch was converted to an ordinal scalee of 0 to 3 and then multiplied by the investigator's total affected area score (0-6)) for a maximum itch score of 18. The EASI was summed with the itch scoree for a maximum mEASI of 90 (the sum of 72 and 18). Investigators also assessedd overall clinical improvement using the following terms: cleared, 100%; excellent,, 90% to 99%; marked, 75% to 89%; moderate, 50% to 74%; slight] 30%>> to 49%; no appreciable improvement, 0% to 29%; and worse, less than 0%. .
Statisticall analyses
Thee e valuable population comprised patients who received at least 1 applicationn of tacrolimus and had at least 1 assessment after baseline. Data were summarizedd by descriptive statistics and frequency counts. The Mérieux score includedd only data from patients who had at least 1 positive reaction. A global dictionary,, based on COSTART (coding symbols for thesaurus of adverse reactionn terms), was used to code investigator terms. Some COSTART terms warrantt explanation. The COSTART term "flu syndrome" was used to code investigatorr terms such as "cold," "common cold," "flu," "influenza," and "upperr respiratory tract infection." Investigator terms for the COSTART term "infection"" included "tonsillitis" and "viral infection," and "allergic reaction" wass used to summarize events such as "conjunctivitis" and "rhinitis." "Alcohol intolerance"" refers to facial flushing or facial skin irritation after consumption of alcoholicc beverages. "Lack of drug effect" was used for investigator terms describingg exacerbation or worsening of atopic dermatitis. "Skin burning" was usedd to refer to the sensation of skin burning or smarting. Adverse events were summarizedd by frequency counts. Cox regression analyses were used to assess anyy effect of cumulative ointment use on the time to first occurrence of selected adversee events.
RESULTS S
Patients s
Off 341 patients screened, 316 were eligible for study entry. Two hundred patientss were assigned to treatment for 6 months and 116 for 12 months. In total,, 245 patients (77.5%) completed the study; 246 patients completed at least 66 months of therapy and 68 completed at least 12 months of therapy. Patient demographicc and baseline characteristics are presented in Table 1 . Comparisonn of the mean age of patients (31 years in the total study population) withh the mean duration of atopic dermatitis (25 years in the total study population)) indicates that most patients experienced onset of the disease during childhood.. The long duration of the current episode (with a mean of several years)) reflects a patient population with persistent disease. The affected body surfacee area was extensive at baseline (a median of approximately one third of totall body surface area), and most patients had active disease on all body regions,, including the head and neck. In total, 162 patients (51.3%) had a historyy of hay fever, 155 (49.0%) had a history of asthma, and 198 (62.7%) had otherr types of allergies; 259 patients (82.0%) had family members with a historyy of atopy. SAFETY The most common adverse events were related to locall irritation; these were burning sensation, pruritus, and skin erythema ( Nonappll I Gallon Site e 12(3.8) ) 19(6.0) ) 10(3.2) ) 77 (2.2) 88 (2.5) 19(6.0) ) 200 (6.3) 33 (0.9) 3(0.9) ) 3(0.9) ) Tolaa If 148(46.8) ) 800 (25.3) 39(12.3) ) 344 (10.8) 411 (13,0) 35(11.1) ) 300 (9.5) 19(6.0) ) 13(4.1) ) 20(6.3) ) "Based"Based on COSTART (coding symbols for thesaurus of adverse reaction terms}. terms}.
Tablee 1. Patient Demographic and Baseline Disuse Characteristics and Reasons lor Withdrawal From the Study
tt Overall incidence of events that occurred exclusively at a treated site, at aa treated site and a nontreated site, or exclusively at a nontreated site.
Inn practice, pruritus seemed related to burning; patients reported these events in thee context of local discomfort. The incidence and intensity of these adverse events,, particularly skin burning, decreased with time. For example, the incidencee of skin burning at the application site was 45.3% of patients during dayss 1 to 4, 22.8% during days 5 to 8, and 7.9% during days 23 to 30. During monthss 10 to 12, only 2.1% of patients experienced this event. The higher incidencee of events that occurred exclusively at a treated site compared with the incidencee of those that occurred in a patient at both a treated and nontreated site (Tablee 2) suggests that skin burning, pruritus, skin erythema, folliculitis, herpes simplex,, alcohol intolerance, and maculopapular rash were specific for the area off application. More than 90% of all patients treated the face, and herpes simplexx (mostly labial) and alcohol intolerance ("facial flushing") were, by nature,, localized on the face; thus, their relation to localized treatment is not clear.. Folliculitis, maculopapular rash, and pustular rash are suspected to be relatedd to the occlusive properties of the ointment. Because lack of drug effect andd skin infection were not localized to the treated area (Table 2) , these events probablyy represent a generalized flare-up of the disease. The most common nonapplicationn site events (irrespective of causality) during the 12-month study weree flu syndrome (69/316, 21.8%); allergic reaction (66/316, 20.9%); infection 120 0
TacrolimusTacrolimus ointment in adults (45/316,, 14.2%); headache (32/316, 10.1%); herpes simplex (20/316, 6.3%); andd asthma, pharyngitis, and rhinitis (each 15/316, 4.7%). Flu syndrome was reportedd most frequently during the winter months. There was otherwise no increasee in the prevalence of any infection over time. In total, 6 patients (1.9%) experiencedd eczema herpeticum. There were 5 serious adverse events for which aa causal relation with the study drug was unknown or considered possible; all weree associated with hospitalization. These constituted 1 patient who experiencedd a severe flare-up of atopic dermatitis, 1 who experienced a Staphylococcuss superinfection of the skin, 1 with eczema herpeticum (the patientt had a long history of relapses), 1 with varicella, and 1 with cellulitis. All butt cellulitus were present on the application site. Cox regression analyses were performedd to assess the effect of cumulative ointment use on the time to first occurrencee of skin infection, nonskin infection, adverse events of the digestive system,, adverse events of the nervous system, and severe related adverse events thatt required medical intervention. No significant increase in the risk of these typess of adverse events was found with increased cumulative ointment use. Laboratoryy measurements showed mean eosinophil counts and lactate dehydrogenasee concentrations greater than the reference range at baseline and alll study visits, as expected for this study population.3, 4 All other mean laboratoryy values were within the reference range during the study and showed noo marked changes over time. One patient experienced an increase in transaminasee levels that resolved before treatment discontinuation. Median wholee blood concentrations of tacrolimus were minimal during the study: 0.32 ng/mLL at 1 week, 0.30 ng/mL at 2 weeks, 0.26 ng/mL at 1 month, 0.18 ng/mL att 3 months, 0.14 ng/mL at 6 months, and 0.13 ng/mL at 12 months. Throughoutt the study, a maximum concentration of less than 1 ng/mL was observedd in 74.7% of patients (236/316), of 1 to less than 2 ng/mL in 16.8% of patientss (53/316), and of 2 to less than 5 ng/mL in 5.4% of patients (17/316). Onlyy 1 patient had a maximum concentration of 5 ng/mL or greater (5.75 ng/mL);; all other blood concentrations for this patient were less than 1 ng/mL. Alll tacrolimus blood concentrations within the limit of quantification (0.025 ng/mL)) were transient. Results of the Recall Antigen Test showed a patient populationn with depressed cell-mediated immunity at baseline, but no notable changess were observed with prolonged treatment. Mean Mérieux scores are shownn in Figure 1 . The mean + SD number of positive antigens was 1.3 + 1.2 at 11 day, 1.5 + 1.3 at 6 months, and 1.8 + 1.4 at 12 months. The proportion of patientss with no positive reactions was also similar over time: 28 patients (33.3%)) at 1 day, 16 (26.2%) at 6 months, and 5 (25.0%) at 12 months. 
Efficacy y
Thee greatest decrease in symptoms, as measured by the mEASI, was seen duringg the first week of treatment ( Figure 2 ). The mEASI continued to decrease untill month 3, and maximal improvement was maintained during the rest of the study.. Decreases in affected body surface area showed the same trend over time (Figuree 2). The size of the treated area over time was nearly identical to the size off the affected area (data not shown). Ointment use also decreased; median dailyy ointment use was 3.9, 2.5, 2.0, and 2.3 g during months 1, 3, 6, and 12, respectively.. The investigator's assessment of global improvement (Figure 3) showss that a substantial proportion of patients experienced at least marked (75%-100%)) improvement by the end of the first week of treatment. As the studyy progressed, more patients experienced at least excellent (90%-100%) improvement.. In terms of overall improvement, Figure 4 shows photographs of thee face and neck of a woman before and after 8 days of treatment with 0.1% tacrolimuss ointment. Figure 5 shows clinical improvement of atopic lesions on thee legs after 6 months of treatment in a woman who had skin atrophy at baseline. . 
COMMENT T
Thiss is the first study to assess the long-term safety and efficacy of tacrolimus ointmentt in adults with atopic dermatitis. The long-term (up to 1 year) safety profilee of tacrolimus ointment observed in this study was similar to that of short-termm trials. We surmise that the heightened local irritation at the start of treatmentt can be accounted for by the baseline disease severity and that the skin becomess more tolerant to the application of any agent as it heals during treatment.. Apart from adverse events related to local irritation, the safety data collectedd in this study reflect concomitant illnesses and complications generally associatedd with atopic dermatitis. Adverse events not indicative of local irritationn were mostly related to atopic dermatitis, atopy in general, infections associatedd with atopic dermatitis, and seasonal infections such as influenza. Givenn that there was no increase in any type of infection with prolonged treatment,, and the overall incidence of infections was consistent with that anticipatedd for this patient population and follow-up period, it seems unlikely thatt tacrolimus ointment use contributes to an increased risk of infection. The skinn of patients with atopic dermatitis is prone to colonization with aerobic bacteriaa and skin infection. 19 In a pediatric study20 with a mean follow-up of 133 months, 40% of patients experienced skin infection compared with 11% of patientss in the present study. Patients with atopic dermatitis are also at high risk forr recurrent herpes simplex infections. More than 5 episodes of cold sores per yearr were noted in approximately 8% of adult patients who had been hospitalizedd at least once during their childhood for atopic dermatitis compared withh less than 1% in a control population.21 Relative to these data, the incidencee of herpes simplex in the present study was consistent with that expectedd for this patient population and duration of observation. Eczema herpeticumm is a complication of atopic dermatitis arising from herpes simplex infectionn that resembles varicella.22 Because cell-mediated immunity is critical forr protection against recurrent viral infections, it has been proposed that the compromisedd cell-mediated immunity in patients with atopic dermatitis is responsiblee for their increased susceptibility to viral superinfections of the skin andd the frequent recurrence of lower-grade viral skin infections.23 Compared withh the incidence of eczema herpeticum demonstrated in a survey24 conducted att a single university clinic, which showed an incidence of approximately 12 patientss per year from 1982 to 1986, the incidence observed in the present study (66 patients) is not remarkable. Findings from the Recall Antigen Test suggest thatt long-term treatment with tacrolimus ointment had no effect on circulating cell-mediatedd immunity. Consistent with results of previously published studies,233 a depressed cell-mediated immunity was observed at baseline. No changee with long-term treatment was observed. Thus, any systemic immunosuppressionn seems unlikely. Systemic absorption of tacrolimus was minimal.. The lack of a skin atrophogenic effect is a major advantage of tacrolimuss ointment compared with conventional treatment with topical corticosteroids.. 12 Although it was not assessed systematically in this study, we suspectt that the reversal of skin atrophy associated with long-term tacrolimus ointmentt use ( Figure 5 ) was a result of the discontinuation of topical corticosteroidd use. This is the first study, to our knowledge, in which topical corticosteroidss were withheld from patients with atopic dermatitis for a prolongedd period. To further evaluate this, it would be useful to assess collagen synthesiss and skin thickness during long-term tacrolimus treatment. The results off this study are consistent with the time to improvement of atopic dermatitis observedd previously in short-term, vehicle-controlled efficacy trials,7-10 ie, improvementt was apparent by the first week of treatment. All efficacy parametersthee mEASI, the investigator's global assessment, and the investigator'ss assessment of the affected areashowed greatest improvement after 11 week of treatment, continued increases in improvement until approximately monthh 3 of treatment, and maintenance of maximal improvement during prolongedd treatment. However, these findings are limited in the context of a noncomparative,, open-label design. In conclusion, the results of this study demonstratee that long-term treatment with tacrolimus ointment is safe and well toleratedd in patients with moderate to severe atopic dermatitis. Local irritation seemedd to be the only adverse event clearly related to the use of tacrolimus ointment;; no systemic toxic effects were apparent. Clinical improvement was apparentt after 1 week of treatment, and maximal improvement was maintained withh prolonged treatment. This agent represents a promising new treatment for atopicc dermatitis.
